30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Precision BioSciences Inc (DTIL)

Track

The most recent insider trading activity occurred on February 18, 2026, with multiple officers and executives, including the President and CEO, engaging in proposed and planned sales of company stock. These transactions involved a significant number of shares across several insiders, indicating a notable divestment pattern.
Stock chart
Ticker: DTIL Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
SMITH J. JEFFERSON
Chief Research Officer
2 sales — total 37,841 USD
Planned sale 18 Feb 2026
Value US$4,948,685.74 | Price 105.44 | Shares 97,488
Proposed sale 18 Feb 2026
Value US$2,689,979.37 | Price 332.15 | Shares 5,619
Planned sale 18 Feb 2026
Value US$1,346,172.53 | Price 363.80 | Shares 33,555
Proposed sale 18 Feb 2026
Value US$3,037,907.72 | Price 71.22 | Shares 34,936
Planned sale 18 Feb 2026
Value US$31,292.16 | Price 3.84 | Shares 8,149
Proposed sale 18 Feb 2026
Value US$31,320.68 | Price 3.84 | Shares 8,149
Planned sale 18 Feb 2026
Value US$18,912.00 | Price 3.84 | Shares 4,925
Proposed sale 18 Feb 2026
Value US$18,929.24 | Price 3.84 | Shares 4,925
Proposed sale 22 Jan 2026
Value US$145,202.30 | Price 4.17 | Shares 34,799
Planned sale 22 Jan 2026
Value US$145,111.83 | Price 4.17 | Shares 34,799
Planned sale 21 Jan 2026
Value US$61,308.39 | Price 4.03 | Shares 15,213
Proposed sale 21 Jan 2026
Value US$61,259.71 | Price 4.03 | Shares 15,213
Planned sale 21 Jan 2026
Value US$41,106.00 | Price 4.03 | Shares 10,200
Proposed sale 21 Jan 2026
Value US$41,073.36 | Price 4.03 | Shares 10,200
Planned sale 21 Jan 2026
Value US$35,681.62 | Price 4.03 | Shares 8,854
Proposed sale 21 Jan 2026
Value US$35,653.29 | Price 4.03 | Shares 8,854
Buy 16 Dec 2025
Value US$14,160.00 | Price 4.72 | Shares 3,000
Buy 16 Dec 2025
Value US$12,690.00 | Price 4.70 | Shares 2,700
Buy 15 Dec 2025
Value US$6,863.57 | Price 4.97 | Shares 1,381
Planned sale 3 Nov 2025
Value US$4,315.85 | Price 6.49 | Shares 665
Proposed sale 3 Nov 2025
Value US$4,315.19 | Price 6.49 | Shares 665
Planned sale 3 Nov 2025
Value US$22,124.41 | Price 6.49 | Shares 3,409
Proposed sale 3 Nov 2025
Value US$22,121.00 | Price 6.49 | Shares 3,409
Planned sale 3 Nov 2025
Value US$8,456.47 | Price 6.49 | Shares 1,303
Proposed sale 3 Nov 2025
Value US$8,455.17 | Price 6.49 | Shares 1,303
Buy 26 Sep 2025
Value US$13,419.00 | Price 4.97 | Shares 2,700
Buy 22 Sep 2025
Value US$6,846.00 | Price 4.89 | Shares 1,400
Planned sale 3 Jul 2025
Value US$63,163.02 | Price 4.26 | Shares 14,827
Proposed sale 3 Jul 2025
Value US$63,207.50 | Price 4.26 | Shares 14,827
Buy 25 Jun 2025
Value US$21,116.16 | Price 4.16 | Shares 5,076
Buy 25 Jun 2025
Value US$6,963.48 | Price 4.14 | Shares 1,682
Buy 26 Mar 2025
Value US$8,735.25 | Price 4.75 | Shares 1,839
Buy 26 Mar 2025
Value US$21,122.41 | Price 4.67 | Shares 4,523
Buy 25 Mar 2025
Value US$17,225.00 | Price 5.30 | Shares 3,250
Planned sale 24 Mar 2025
Value US$5,359.84 | Price 5.56 | Shares 964
Proposed sale 24 Mar 2025
Value US$5,355.41 | Price 5.56 | Shares 964
Proposed sale 5 Mar 2025
Value US$1,684.25 | Price 5.06 | Shares 333
Planned sale 4 Mar 2025
Value US$756.14 | Price 4.91 | Shares 154
Proposed sale 4 Mar 2025
Value US$756.16 | Price 4.91 | Shares 154
Planned sale 4 Mar 2025
Value US$1,335.52 | Price 4.91 | Shares 272
Proposed sale 4 Mar 2025
Value US$1,335.55 | Price 4.91 | Shares 272
Proposed sale 24 Jan 2025
Value US$3,386.61 | Price 5.04 | Shares 672
Proposed sale 22 Jan 2025
Value US$42,726.73 | Price 4.79 | Shares 8,928
Planned sale 22 Jan 2025
Value US$42,765.12 | Price 4.79 | Shares 8,928
Proposed sale 22 Jan 2025
Value US$49,230.49 | Price 4.79 | Shares 10,287
Planned sale 22 Jan 2025
Value US$49,274.73 | Price 4.79 | Shares 10,287
Planned sale 21 Jan 2025
Value US$172,033.46 | Price 4.67 | Shares 36,838
Proposed sale 21 Jan 2025
Value US$172,162.39 | Price 4.67 | Shares 36,838
Buy 30 Dec 2024
Value US$16,186.45 | Price 4.49 | Shares 3,605
Buy 27 Dec 2024
Value US$10,036.75 | Price 4.75 | Shares 2,113
Buy 27 Dec 2024
Value US$21,081.60 | Price 4.88 | Shares 4,320
Buy 26 Dec 2024
Value US$13,722.80 | Price 4.55 | Shares 3,016
Buy 21 Nov 2024
Value US$20,280.00 | Price 6.76 | Shares 3,000
Sale 4 Nov 2024
Value US$24,668.28 | Price 8.19 | Shares 3,012
Proposed sale 4 Nov 2024
Value US$24,669.48 | Price 8.19 | Shares 3,012
Planned sale 4 Nov 2024
Value US$4,815.72 | Price 8.19 | Shares 588
Proposed sale 4 Nov 2024
Value US$4,815.96 | Price 8.19 | Shares 588
Planned sale 10 Jun 2024
Value US$1,096.47 | Price 11.79 | Shares 93
Proposed sale 10 Jun 2024
Value US$1,096.03 | Price 11.79 | Shares 93
Sale 10 Jun 2024
Value US$589.50 | Price 11.79 | Shares 50
Proposed sale 10 Jun 2024
Value US$589.27 | Price 11.79 | Shares 50
Planned sale 2 May 2024
Value US$2,992.80 | Price 10.32 | Shares 290
Proposed sale 2 May 2024
Value US$2,993.21 | Price 10.32 | Shares 290
Planned sale 2 May 2024
Value US$2,807.04 | Price 10.32 | Shares 272
Planned sale 2 May 2024
Value US$2,807.04 | Price 10.32 | Shares 272
Proposed sale 2 May 2024
Value US$2,807.42 | Price 10.32 | Shares 272
Planned sale 2 May 2024
Value US$15,748.32 | Price 10.32 | Shares 1,526
Proposed sale 2 May 2024
Value US$15,750.46 | Price 10.32 | Shares 1,526
Sale 2 May 2024
Value US$1,589.28 | Price 10.32 | Shares 154
Proposed sale 2 May 2024
Value US$1,589.50 | Price 10.32 | Shares 154
Proposed sale 30 Apr 2024
Value US$2,386.43 | Price 10.03 | Shares 238
Planned sale 30 Apr 2024
Value US$2,386.43 | Price 10.03 | Shares 238
Proposed sale 23 Jan 2024
Value US$10,325.61 | Price 0.37 | Shares 28,000
Sale 23 Jan 2024
Value US$10,360.00 | Price 0.37 | Shares 28,000
Planned sale 22 Jan 2024
Value US$7,749.36 | Price 0.36 | Shares 21,526
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-19 2026-02-18 PlS Planned sale
2.4
SMITH J. JEFFERSON

Chief Research Officer

Officer
97,488 -19.3%
105.44
US$4,948,686 		97,488 -19.3% 105.44 US$4,948,686
2026-02-19 2026-02-18 PlS Planned sale
3.4
Amoroso Michael

President and CEO

Executive Director
33,555 +16.1%
363.80
US$1,346,173 		33,555 +16.1% 363.80 US$1,346,173
2026-02-19 2026-02-18 PlS Planned sale
2.1
Kelly John Alexander

Chief Financial Officer

Officer
47,456 +41.7%
441.85
US$4,349,307 		47,456 +41.7% 441.85 US$4,349,307
2026-02-19 2026-02-18 PlS Planned sale
Scimeca Dario

General Counsel and Secretary

Officer
4,925 -8.0%
3.84
US$18,912 		4,925 -8.0% 3.84 US$18,912
2026-02-18 2026-02-18 PrS Proposed sale
2.4
SMITH J. JEFFERSON

Officer

Officer
4,925
3.84
US$18,929 		4,925 3.84 US$18,929
2026-02-18 2026-02-18 PrS Proposed sale
Scimeca Dario

Officer

Officer
4,925
3.84
US$18,929 		4,925 3.84 US$18,929
2026-02-18 2026-02-18 PrS Proposed sale
3.4
Amoroso Michael

Officer; Director

Executive Director
20,559
3.84
US$79,019 		20,559 3.84 US$79,019
2026-02-18 2026-02-18 PrS Proposed sale
2.1
Kelly John Alexander

Officer

Officer
8,149
3.84
US$31,321 		8,149 3.84 US$31,321
2026-01-22 2026-01-22 PrS Proposed sale
3.4
Amoroso Michael

Officer; Director

Executive Director
34,799
4.17
US$145,202 		34,799 4.17 US$145,202
2026-01-22 2026-01-22 PlS Planned sale
3.4
Amoroso Michael

President and CEO

Executive Director
34,799 -15.1%
4.17
US$145,112 		34,799 -15.1% 4.17 US$145,112
2026-01-22 2026-01-21 PlS Planned sale
2.1
Kelly John Alexander

Chief Financial Officer

Officer
15,213 -12.5%
4.03
US$61,308 		15,213 -12.5% 4.03 US$61,308
2026-01-22 2026-01-21 PlS Planned sale
2.4
SMITH J. JEFFERSON

Chief Research Officer

Officer
10,200 -8.5%
4.03
US$41,106 		10,200 -8.5% 4.03 US$41,106
2026-01-22 2026-01-21 PlS Planned sale
Scimeca Dario

General Counsel and Secretary

Officer
8,854 -16.5%
4.03
US$35,682 		8,854 -16.5% 4.03 US$35,682
2026-01-21 2026-01-21 PrS Proposed sale
Scimeca Dario

Officer

Officer
8,854
4.03
US$35,653 		8,854 4.03 US$35,653
2026-01-21 2026-01-21 PrS Proposed sale
2.4
SMITH J. JEFFERSON

Officer

Officer
10,200
4.03
US$41,073 		10,200 4.03 US$41,073
2026-01-21 2026-01-21 PrS Proposed sale
2.1
Kelly John Alexander

Officer

Officer
15,213
4.03
US$61,260 		15,213 4.03 US$61,260
2025-12-17 2025-12-16 B Purchase
2.8
Germano Geno J
Non-Executive Director
3,000 +14.4%
4.72
US$14,160 		3,000 +14.4% 4.72 US$14,160
2025-12-17 2025-12-16 B Purchase
2.9
Frankel Stanley
Non-Executive Director
2,700 +16.1%
4.70
US$12,690 		2,700 +16.1% 4.70 US$12,690
2025-12-17 2025-12-15 B Purchase
3.5
Brown Melinda
Non-Executive Director
1,381 +6.3%
4.97
US$6,864 		1,381 +6.3% 4.97 US$6,864
2025-11-04 2025-11-03 PlS Planned sale
Scimeca Dario

General Counsel and Secretary

Officer
665 -2.3%
6.49
US$4,316 		665 -2.3% 6.49 US$4,316
2025-11-04 2025-11-03 PlS Planned sale
3.4
Amoroso Michael

President and CEO

Executive Director
3,409 -2.9%
6.49
US$22,124 		3,409 -2.9% 6.49 US$22,124
2025-11-04 2025-11-03 PlS Planned sale
2.1
Kelly John Alexander

Chief Financial Officer

Officer
1,303 -1.7%
6.49
US$8,456 		1,303 -1.7% 6.49 US$8,456
2025-11-03 2025-11-03 PrS Proposed sale
2.1
Kelly John Alexander

Officer

Officer
1,303
6.49
US$8,455 		1,303 6.49 US$8,455
2025-11-03 2025-11-03 PrS Proposed sale
3.4
Amoroso Michael

Officer; Director

Executive Director
3,409
6.49
US$22,121 		3,409 6.49 US$22,121
2025-11-03 2025-11-03 PrS Proposed sale
Scimeca Dario

Officer

Officer
665
6.49
US$4,315 		665 6.49 US$4,315
2025-09-30 2025-09-26 B Purchase
2.9
Frankel Stanley
Non-Executive Director
2,700 +19.2%
4.97
US$13,419 		2,700 +19.2% 4.97 US$13,419
2025-09-24 2025-09-22 B Purchase
3.5
Brown Melinda
Non-Executive Director
1,400 +6.8%
4.89
US$6,846 		1,400 +6.8% 4.89 US$6,846
2025-07-08 2025-07-03 PlS Planned sale
2.1
Kelly John Alexander

Chief Financial Officer

Officer
14,827 -16.8%
4.26
US$63,163 		14,827 -16.8% 4.26 US$63,163
2025-07-03 2025-07-03 PrS Proposed sale
2.1
Kelly John Alexander

Officer

Officer
14,827
4.26
US$63,208 		14,827 4.26 US$63,208
2025-06-27 2025-06-25 B Purchase
3.5
Buehler Kevin
Non-Executive Director
5,076 +22.0%
4.16
US$21,116 		5,076 +22.0% 4.16 US$21,116
2025-06-27 2025-06-25 B Purchase
3.5
Brown Melinda
Non-Executive Director
1,682 +8.9%
4.14
US$6,963 		1,682 +8.9% 4.14 US$6,963
2025-03-28 2025-03-26 B Purchase
3.5
Brown Melinda
Non-Executive Director
1,839 +25.5%
4.75
US$8,735 		1,839 +25.5% 4.75 US$8,735
2025-03-28 2025-03-26 B Purchase
3.5
Buehler Kevin
Non-Executive Director
4,523 +51.9%
4.67
US$21,122 		4,523 +51.9% 4.67 US$21,122
2025-03-27 2025-03-25 B Purchase
2.8
Germano Geno J
Non-Executive Director
3,250 +41.6%
5.30
US$17,225 		3,250 +41.6% 5.30 US$17,225
2025-03-25 2025-03-24 PlS Planned sale
3.4
Amoroso Michael

President and CEO

Executive Director
964 -0.9%
5.56
US$5,360 		964 -0.9% 5.56 US$5,360
2025-03-24 2025-03-24 PrS Proposed sale
3.4
Amoroso Michael

Officer; Director

Executive Director
964
5.56
US$5,355 		964 5.56 US$5,355
2025-03-05 2025-03-05 PrS Proposed sale
List Alan

Officer

Officer
333
5.06
US$1,684 		333 5.06 US$1,684
2025-03-05 2025-03-04 PlS Planned sale
2.4
SMITH J. JEFFERSON

Chief Research Officer

Officer
154 -0.2%
4.91
US$756 		154 -0.2% 4.91 US$756
2025-03-05 2025-03-04 PlS Planned sale
Scimeca Dario

General Counsel and Secretary

Officer
272 -1.1%
4.91
US$1,336 		272 -1.1% 4.91 US$1,336
2025-03-04 2025-03-04 PrS Proposed sale
2.4
SMITH J. JEFFERSON

Officer

Officer
154
4.91
US$756 		154 4.91 US$756
2025-03-04 2025-03-04 PrS Proposed sale
Scimeca Dario

Officer

Officer
272
4.91
US$1,336 		272 4.91 US$1,336
2025-01-24 2025-01-24 PrS Proposed sale
List Alan

Officer

Officer
672
5.04
US$3,387 		672 5.04 US$3,387
2025-01-22 2025-01-22 PrS Proposed sale
Scimeca Dario

Officer

Officer
8,928
4.79
US$42,727 		8,928 4.79 US$42,727
2025-01-22 2025-01-22 PrS Proposed sale
2.4
SMITH J. JEFFERSON

Officer

Officer
10,287
4.79
US$49,230 		10,287 4.79 US$49,230
2025-01-22 2025-01-22 PlS Planned sale
Scimeca Dario

General Counsel and Secretary

Officer
8,928 -26.8%
4.79
US$42,765 		8,928 -26.8% 4.79 US$42,765
2025-01-22 2025-01-22 PlS Planned sale
2.4
SMITH J. JEFFERSON

Chief Research Officer

Officer
10,287 -10.5%
4.79
US$49,275 		10,287 -10.5% 4.79 US$49,275
2025-01-22 2025-01-21 PlS Planned sale
3.4
Amoroso Michael

President and CEO

Executive Director
36,838 -25.6%
4.67
US$172,033 		36,838 -25.6% 4.67 US$172,033
2025-01-21 2025-01-21 PrS Proposed sale
3.4
Amoroso Michael

Officer; Director

Executive Director
36,838
4.67
US$172,162 		36,838 4.67 US$172,162
2025-01-02 2024-12-30 B Purchase
2.8
Germano Geno J
Non-Executive Director
3,605 +85.8%
4.49
US$16,186 		3,605 +85.8% 4.49 US$16,186
2024-12-31 2024-12-27 B Purchase
2.1
Kelly John Alexander

Chief Financial Officer

Officer
2,113 +5.5%
4.75
US$10,037 		2,113 +5.5% 4.75 US$10,037
2024-12-31 2024-12-27 B Purchase
3.5
Buehler Kevin
Non-Executive Director
4,320 +98.4%
4.88
US$21,082 		4,320 +98.4% 4.88 US$21,082
2024-12-30 2024-12-26 B Purchase
3.5
Brown Melinda
Non-Executive Director
3,016 +71.8%
4.55
US$13,723 		3,016 +71.8% 4.55 US$13,723
2024-11-21 2024-11-21 B Purchase
2.1
Kelly John Alexander

Chief Financial Officer

Officer
3,000 +8.6%
6.76
US$20,280 		3,000 +8.6% 6.76 US$20,280
2024-11-05 2024-11-04 S Sale
3.4
Amoroso Michael

President and CEO

Executive Director
3,012 -9.5%
8.19
US$24,668 		3,012 -9.5% 8.19 US$24,668
2024-11-05 2024-11-04 PlS Planned sale
Scimeca Dario

General Counsel and Secretary

Officer
588 -6.9%
8.19
US$4,816 		588 -6.9% 8.19 US$4,816
2024-11-04 2024-11-04 PrS Proposed sale
Scimeca Dario

Officer

Officer
588
8.19
US$4,816 		588 8.19 US$4,816
2024-11-04 2024-11-04 PrS Proposed sale
3.4
Amoroso Michael

Officer; Director

Executive Director
3,012
8.19
US$24,669 		3,012 8.19 US$24,669
2024-06-11 2024-06-10 PlS Planned sale
Scimeca Dario

General Counsel and Secretary

Officer
93 -1.4%
11.79
US$1,096 		93 -1.4% 11.79 US$1,096
2024-06-11 2024-06-10 S Sale
2.4
SMITH J. JEFFERSON

Chief Research Officer

Officer
50 -0.1%
11.79
US$590 		50 -0.1% 11.79 US$590
2024-06-10 2024-06-10 PrS Proposed sale
Scimeca Dario

Officer

Officer
93
11.79
US$1,096 		93 11.79 US$1,096
2024-06-10 2024-06-10 PrS Proposed sale
2.4
SMITH J. JEFFERSON

Officer

Officer
50
11.79
US$589 		50 11.79 US$589
2024-05-03 2024-05-02 PlS Planned sale
List Alan

Chief Medical Officer

Officer
290 -6.1%
10.32
US$2,993 		290 -6.1% 10.32 US$2,993
2024-05-03 2024-05-02 PlS Planned sale
Scimeca Dario

General Counsel and Secretary

Officer
272 -4.6%
10.32
US$2,807 		272 -4.6% 10.32 US$2,807
2024-05-03 2024-05-02 PlS Planned sale
Scimeca Dario

General Counsel and Secretary

Officer
272 -4.6%
10.32
US$2,807 		272 -4.6% 10.32 US$2,807
2024-05-03 2024-05-02 PlS Planned sale
3.4
Amoroso Michael

President and CEO

Executive Director
1,526 -10.0%
10.32
US$15,748 		1,526 -10.0% 10.32 US$15,748
2024-05-03 2024-05-02 S Sale
2.4
SMITH J. JEFFERSON

Chief Research Officer

Officer
154 -0.2%
10.32
US$1,589 		154 -0.2% 10.32 US$1,589
2024-05-02 2024-05-02 PrS Proposed sale
List Alan

Officer

Officer
290
10.32
US$2,993 		290 10.32 US$2,993
2024-05-02 2024-05-02 PrS Proposed sale
Scimeca Dario

Officer

Officer
272
10.32
US$2,807 		272 10.32 US$2,807
2024-05-02 2024-05-02 PrS Proposed sale
2.4
SMITH J. JEFFERSON

Officer

Officer
154
10.32
US$1,590 		154 10.32 US$1,590
2024-05-02 2024-05-02 PrS Proposed sale
3.4
Amoroso Michael

Officer; Director

Executive Director
1,526
10.32
US$15,750 		1,526 10.32 US$15,750
2024-04-30 2024-04-30 PrS Proposed sale
List Alan

Officer

Officer
238
10.03
US$2,386 		238 10.03 US$2,386
2024-04-30 2024-04-30 PlS Planned sale
List Alan

Chief Medical Officer

Officer
238 -5.9%
10.03
US$2,386 		238 -5.9% 10.03 US$2,386
2024-01-23 2024-01-23 PrS Proposed sale
2.4
SMITH J. JEFFERSON

Officer

Officer
28,000
0.37
US$10,326 		28,000 0.37 US$10,326
2024-01-23 2024-01-23 S Sale
2.4
SMITH J. JEFFERSON

Chief Research Officer

Officer
28,000 -1.4%
0.37
US$10,360 		28,000 -1.4% 0.37 US$10,360
2024-01-23 2024-01-22 PlS Planned sale
List Alan

Chief Medical Officer

Officer
21,526 -18.5%
0.36
US$7,749 		21,526 -18.5% 0.36 US$7,749
Explore more

More insider trading research around Precision BioSciences Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America